http://www.pharmabiz.com/NewsDetails.aspx?aid=101677&sid=2 not...

http://www.pharmabiz.com/NewsDetails.aspx?aid=101677&sid=2

not good news :/

hopefully this isnt lonsurf mark 2... unfortunately med oncs will still be biased towards using nexavar and then stivarga, especially given the most widely viewed/respected publications commenting on the SARAH result are just looking at the ITT numbers and seem to be ignoring the PP analysis:

http://www.ascopost.com/News/55546

given the not-so-hot result in SARAH, probably preventing FDA label expansion to HCC, im looking to mCRC as the growth driver for SRX